News Releases

IDE397 is being developed as a potential best-in-class MAT2A inhibitor for MTAP-deletion, which is prevalent in approximately 15% of all solid tumors

- IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND-filing in December 2020

- The partnership with the Sellers Laboratory at the Broad Institute of MIT and Harvard will utilize the Broad CRISPR paralog screening platform for Synthetic Lethality target and biomarker discovery, including for IDEAYA's PARG program

- Established strategic partnership with GlaxoSmithKline on Synthetic Lethality programs MAT2A, Pol Theta and Werner Helicase